Monte Rosa Therapeutics (GLUE) Equity Average: 2023-2025
Historic Equity Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $257.0 million.
- Monte Rosa Therapeutics' Equity Average rose 19.48% to $257.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.0 million, marking a year-over-year increase of 19.48%. This contributed to the annual value of $201.1 million for FY2024, which is N/A change from last year.
- Per Monte Rosa Therapeutics' latest filing, its Equity Average stood at $257.0 million for Q3 2025, which was down 5.40% from $271.6 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Equity Average registered a high of $271.6 million during Q2 2025, and its lowest value of $165.9 million during Q1 2024.
- For the 3-year period, Monte Rosa Therapeutics' Equity Average averaged around $217.1 million, with its median value being $214.6 million (2024).
- Per our database at Business Quant, Monte Rosa Therapeutics' Equity Average dropped by 17.53% in 2024 and then spiked by 50.13% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Equity Average (Quarterly) stood at $181.9 million in 2023, then climbed by 17.76% to $214.2 million in 2024, then increased by 19.48% to $257.0 million in 2025.
- Its last three reported values are $257.0 million in Q3 2025, $271.6 million for Q2 2025, and $249.0 million during Q1 2025.